Fri 23 Oct 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| Global cross-sectional burden-of-illness study in adolescent and adult patients with atopic dermatitis (MEASURE-AD) | Abbvie | Ongoing | Drug choice as per treating physician which is not limited per the protocol | 4 | H19-940 | Hira Hospital (Makkah), Security Force Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh) |
| A PROSPECTIVE OBSERVATIONAL STUDY OF ADULT PATIENTS RECEIVING DUPIXENT FOR ATOPIC DERMATITIS | Sanofi | Ongoing | DUPILUMAB | 4 | OBS15990 | King Abdulaziz Medical City NG (Riyadh), King Fahad Specialist Hospital (Dammam) |
| "A Multinational, Prospective, Observational Study of theEffectiveness, Healthcare Resource Utilization and Costsin Patients with Rheumatoid Arthritis ReceivingBaricitinib, Targeted Synthetic or BiologicDisease-Modifying Therapies" | Eli Lilly | Ongoing | Baricitinib | 4 | I4V-MCB009 | Specialized Medical Center (Riyadh), Dr. Sulaiman Al-Habib Medical Group Takhassusi (Riyadh) |
| Guidelines Oriented Approach to Lipid lowering Quality Enhancement Research Initiative (GOAL QuERI) International | Canadian Heart Research Centre | Ongoing | any SFDA registered anti-hyperlipidemic product | 4 | CHRC2019 | King Fahd Armed Forces Hospital (Jeddah), King Fahd Military Medical Complex (Dhahran), King Abdullah Medical Complex (Jeddah), King Fahad Hospital (Jeddah), King Fahad Genaral Hospital (Medina), King Khaled General Hospital (Hafar Al Batin), Royal Commission Hospital Jubail |
| A multicenter, multinational, prospective, observational study to describe the clinical outcomes in patients with Type 2 diabetes mellitus, treated with iGlarLixi fixed ratio combination (SOLIQUA®) before, during and after the period of Ramadan (SoliRam Study) | Sanofi | Ongoing | Soliqua® Solostar | 4 | OBS16049 | University District Hospital (Jeddah), Alzafer Hospital (Najran), Ghassan Najeeb Pharaon hospital (Jeddah) |
| Vortioxetine effectiveness overview for the treated MDE patients in Saudi Arabia | Lundbeck | Ongoing | BRINTELLIX 20 mg film-coated tablet/ BRINTELLIX 10 mg film-coated tablet | 4 | 18620N | King Abdulaziz University Hospital (Jeddah), Saudi German Hospital (Jeddah), Dr. Erfan & Bagedo General Hospital (Jeddah), University Medical Center (Riyadh), Psych care Center (Riyadh), Dr. Sulaiman Al-Habib Medical Group Olaya (Riyadh), Al Moosa Specialized Hospital (al ahsa), King Fahad Medical City (Riyadh), Almana Hospital (Dammam), King Abdullah Medical Complex (Jeddah), Jeddah psychiatric hospital, Elite Medical Complex (Makkah) |
| A multicentre non-interventional study to assess the real-world effectiveness of Ocrelizumab in patients with relapsing or primary progressive multiple sclerosis – The MuSicalE STUDY | Roche | Ongoing | Ocrelizumab (Ocrevus) | 4 | MN39889 | King Abdulaziz Medical City NG (Riyadh) |
| "Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP)" | KAIMRC | Ongoing | • Ceftriaxone • Piperacillin Tazobactam • Azithromycin • Interferon β1-a • Hydrocortisone sodium suc.• Hydroxychloroquine • OSELTAMIVIR • Lopinavir-Ritonavir | 3 | CT20/001/R | King Abdulaziz Medical City NG (Riyadh) |
| A Trial of Favipiravir in Adults with Mild Coronavirus Disease Covid-19 | KAIMRC | Ongoing | Favipiravir | 3 | RC20/220/R | King Abdulaziz Medical City NG (Riyadh) |
| A Trial of Favipiravir and Hydroxychloroquine combination in Adults Hospitalized with moderate and severe Covid-19 | KAIMRC | Ongoing | • Favipiravir• HYDROXYCHLOROQUINE SULPHATE | 3 | RC20/174/R | King Abdulaziz Medical City NG (Riyadh) |
Last update date: 06/10/2026 at 08:14 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.